Article Information
- Received April 13, 2022
- Revision received October 3, 2022
- Accepted October 10, 2022
- First published October 18, 2022.
- Version of record published November 30, 2022.
Author Information
Author contributions
Author contributions: H.-L.P. designed research; J.Z., S.-R.C., M.-H.Z., D.J., H.C., and L.W. performed research; R.A.D. contributed unpublished reagents/analytic tools; J.Z., S.-R.C., M.-H.Z., D.J., H.C., L.W., and H.-L.P. analyzed data; J.Z., S.-R.C., and H.-L.P. wrote the paper.
*J.Z. and S.-R.C. contributed equally to this work.
Disclosures
- Received April 13, 2022.
- Revision received October 3, 2022.
- Accepted October 10, 2022.
This work was supported by National Institutes of Health–National Institute of Neurological Disorders and Stroke Grant NS101880 and the N.G. and Helen T. Hawkins Endowment. We thank Sarah Bronson at MD Anderson Cancer Center for proofreading the manuscript.
The authors are employees of the University of Texas System, which currently holds a patent for targeting α2δ-1–bound glutamate receptors for treating diseases and disorders.
- Correspondence should be addressed to Hui-Lin Pan at huilinpan{at}mdanderson.org
Funding
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
NS101880
Other Version
- previous version (October 18, 2022).
- You are viewing the most recent version of this article.
